Compare EKSO & ALUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EKSO | ALUR |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2M | 18.9M |
| IPO Year | N/A | N/A |
| Metric | EKSO | ALUR |
|---|---|---|
| Price | $7.27 | $1.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $9.50 | $9.25 |
| AVG Volume (30 Days) | ★ 5.9M | 87.0K |
| Earning Date | 03-02-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $14,749,000.00 | ★ $17,208,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $54.65 | $15.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.73 | $1.02 |
| 52 Week High | $12.70 | $16.81 |
| Indicator | EKSO | ALUR |
|---|---|---|
| Relative Strength Index (RSI) | 48.80 | 48.00 |
| Support Level | $7.70 | $1.65 |
| Resistance Level | $9.11 | $1.93 |
| Average True Range (ATR) | 1.09 | 0.17 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 1.29 | 52.48 |
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.